益心通络胶囊预防冠脉支架植入术后再狭窄的近期效应和安全性的研究

《益心通络胶囊预防冠脉支架植入术后再狭窄的近期效应和安全性的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、提要目的：探讨医疗机构内制剂益心通络胶囊预防冠脉支架植入术后再狭窄的近期效应、安全性及其作用机理。方法：将160例冠脉内支架植入成功的冠心病患者，随机分为对照组和治疗组，对照组常规服用阿司匹林片100mg，每日1次，氯吡格雷片75mg，每日1次。治疗组在对照组的基础上加用益心通络胶囊。两组疗程均为6个月。结果：观察术后6个月冠脉造影再狭窄率、晚期内径数值，对血清学指标、心电图、临床症状的影响。以上差异均有统计学意义(P＜0.05)。两组用药期间不良反应率差异无统计学意义（P＞0.05)。结论：益心通络胶囊能显著改善冠脉支架植入术后患者气血瘀痰

2、阻的状态，减轻早期术后机体对冠脉支架的炎症反应，提高机体免疫功能，减少术后再狭窄的发生率，且无明显不良反应。该药对预防ISR是有效和安全的。关键词益心通络胶囊；预防；冠心病；支架植入再狭窄。TheshorttermeffectandsafetystudyabouttheYixintongluoCapsulepreventingrestenosisaftercoronarystentimplantationSpeciality:CardiovascularDiseaseMedicineofTCMAuthor:ZhangXinyuanTutor:

3、prof.LiYunlunAbstractObjective：Toexplorethetreatmentandpreventionfunctionofself-prescribedChineseprescriptionofrestenosisafterstentimplantationandtoexplorethemechanism.Method：160coronaryarterydiseasepatientsafterstentimplantationinourhospitalweredividedrandomlyintocontrolle

4、dandtreatedgroups，controlledgrouppatientsconventionaltookaspirin100mgqd，clopidogreltablets(Plavix)75mgqd.Thetreatedgrouppatientsacceptedthesametheropyofcontrolledgroup，besidethattheyalsotookYixintongluocapsuleinventedbymyhospital,2piecesbid.Twogroupstookclopidogrelonlyforsi

5、xmonths.Yixintongluocapsuleandaspirinweretakencontinuousiy.Periodoftreatmentissixmonths.Results：Aftertreatment，thetwogroupsaftertreatmentdecreasedsignificantly，thetreatedtgroupdecreasedgreatly；BloodstasissyndromeintegralandQideficiencyintegralofthewogroupsdecreasedsignifica

6、ntly，thetreatedgroupdecreasedgreatly.Conclusion：ClinicalandexperimentalstudyaffirmedTraditionalChineseherbscanreducetheincidenceofISR，ImproveQideficiencyandbloodstasisofpostoperativepatients，reducingcoronarystentinflammation，immuneresponseofearlypostoperativebody，enhanceimm

7、unefunction，inhibitinflammation，preventtheoccurrenceofISR.ThecapsuleiseffectiveandsafeforthepreventionofISR.YixintongluoCapsulecanreducepostoperativerestenosis，hasnoobviousadversereaction.KeywordsYixintongluoCapsule；prevention；coronaryheartdisease；StentImplantationRestenosi

8、s；0目录引言...........................................................................